Glypvilo

Glypvilo is a prescription medication that contains the active ingredient vildagliptin, a dipeptidyl peptidase‑4 (DPP‑4) inhibitor, supplied in oral tablet form for use in the European Union. It belongs to the antidiabetic (oral hypoglycemic) therapeutic class and works by enhancing the body’s own insulin response to glucose.

Glypvilo is indicated for the management of type 2 diabetes mellitus as part of a comprehensive treatment plan that includes diet and exercise. It may be used alone or in combination with other antidiabetic agents.

- Improves glycemic control in adults with type 2 diabetes. - Can be combined with metformin when monotherapy is insufficient. - May be added to sulfonylureas to achieve target HbA1c levels. - Used when lifestyle modifications alone do not maintain adequate blood glucose. - Considered for patients who prefer oral therapy over injectable options.

Side effects of Glypvilo vary in frequency and severity. Most are mild and transient, while a few require medical attention.

Common: - Upper respiratory tract infection - Headache - Dizziness - Nausea - Diarrhea - Joint pain

Serious: - Pancreatitis (severe abdominal pain) - Severe allergic reactions (rash, swelling, difficulty breathing) - Hepatic dysfunction (elevated liver enzymes) - Hypoglycemia when combined with insulin or sulfonylureas

Before starting Glypvilo, certain health considerations should be reviewed to ensure safe use.

- Assess renal function; dose adjustment may be needed in impaired kidneys. - Monitor liver enzymes periodically during therapy. - Use caution in patients with a history of pancreatitis. - Evaluate cardiovascular status, as some patients may experience fluid retention. - Discuss pregnancy and breastfeeding plans with a healthcare professional. - Review any history of allergic reactions to DPP‑4 inhibitors.

Glypvilo can interact with several medications, influencing its effectiveness or safety profile.

Avoid: - Strong CYP3A4 inhibitors (e.g., ketoconazole) that may increase vildagliptin levels. - Concurrent use with other DPP‑4 inhibitors. - High-dose insulin or sulfonylureas without dose adjustment due to hypoglycemia risk.

Use with caution: - Diuretics, as fluid balance changes may affect blood glucose. - Anticoagulants, monitoring for any alteration in INR. - Rifampin, which may reduce vildagliptin exposure. - NSAIDs, for potential renal function impact.